The FDA has granted AUTX-703, a first-in-class oral KAT2A/B degrader, fast track designation for the treatment of ...

Ryvu Therapeutics is shrinking its headcount by 30% as the Polish biotech focuses its funds on taking its lead blood cancer ...

LUND, SE / ACCESS Newswire / February 25, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) invites investors, analysts, and the press to a presentation of the Year-end report 20 ...

Kangpu Biopharmaceuticals, Ltd. ('Kangpu') today announced that the Company has received IND approval from the CDE (Center ...

LUND, SE / ACCESS Newswire / February 25, 2025 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) invites ...

Advisor engaged in evaluating strategic options to maximize shareholder valueCash balance of $76.6 million as of December 31, 2024UTRECHT, The ...

Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies ...

The Food and Drug Administration granted fast track designation to AUTX-703 for relapsed or refractory acute myelogenous ...

Two new cancer doctors with expertise in melanoma and bone cancer and stem cell transplantation have joined Upstate Cancer Center. Dr. Jade Homsi will serve as division chief of hematology and ...

Dr. Marc Hedrick, Rick Hawkins, and Russell Bradley Join CNSide Board of Directors. Dr. Jonathan Stein Appointed CNSid ...

Researchers identify associations between B12 levels currently accepted as normal and markers of neurological injury or ...

Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the first patient has been included in the phase Ib/II clinical study of tasquinimod in patients with myelofibrosis ...